Ask AI
CELMoDs in Myeloma

CE / CME

CELMoDs in Myeloma—What’s Here, What’s Next, and What’s on the Horizon

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.25 Medical Knowledge MOC points

Released: June 26, 2025

Expiration: December 25, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following best describes differences between novel CELMoDs and approved IMiDs in regulating myeloma cell proliferation and modulating immune responses?

2.

In your current practice, how likely would you be to consider a treatment for multiple myeloma that was FDA-approved based on MRD-negative CR data?

3.

Which investigational CELMoD is currently being evaluated in phase III trials enrolling patients with multiple myeloma in the post-ASCT maintenance and relapsed/refractory settings?